Zepbound and Wegovy Savings Cards vs Patient Assistance: Who Qualifies

The short answer

The Zepbound and Wegovy savings cards only help if commercial insurance covers the drug. Then you can pay as little as $25 a month. The free-drug programs don't help with weight loss: as of October 2026, neither Lilly Cares nor Novo Nordisk's assistance program lists Zepbound or Wegovy. Self-pay at $149 to $449 is the real fallback.

That is not the answer most search results give you. Type "Zepbound patient assistance program" into a search bar and a lot of what comes back is PDF spam and pages promising free medication. We read the manufacturers' own program lists the day this was written. Below is what they actually say, program by program, so you can stop filling out applications that can't succeed.

Three different things with similar names

Who the savings card actually helps

The card is a copay program. It pays part of the bill after your insurance pays its share. Lilly says commercially insured patients whose plan covers Zepbound may pay as little as $25 for a one- or three-month supply. There are monthly and annual limits, and government beneficiaries are excluded.¹ Novo's Wegovy card works the same way: as little as $25, with savings capped at $100 for a one-month fill. It excludes anyone enrolled in Medicare, Medicaid, the VA, TRICARE or a similar program.²

That $100 cap is the detail people miss. If your plan's copay for Wegovy is $300, the card takes $100 off and you pay $200, not $25. The headline number assumes a plan that already does most of the work.

If your plan doesn't cover the drug at all, the card is not a workaround. The better question becomes whether you have a diagnosis that the plan does cover. Sleep apnea for Zepbound and heart disease for Wegovy are the main ones, and we walk through them in how to get Zepbound covered with a metabolic diagnosis.

Lilly Cares and Novo's program: are these drugs even on the list?

No. This is the honest answer the spam pages bury.

Lilly Cares. Lilly's foundation publishes a list of the medicines it provides. As of October 2026 it includes insulins and Trulicity, a diabetes drug, among others. Zepbound is not on it, and neither are Mounjaro or Foundayo.³ If a site says Lilly Cares will send you Zepbound for weight loss, check the list yourself before you share your tax returns with anyone.

Novo Nordisk Patient Assistance Program. Novo's 2026 product list includes Ozempic, insulins and a few other products. Wegovy is not on it. Ozempic is marked as available to uninsured patients only.⁴ The program page states that to qualify in 2026 you must have Medicare or no insurance. Anyone with private or commercial insurance is not eligible, and household income has to fall within limits based on federal poverty guidelines.⁵

So Ozempic through Novo's program is a real option for an uninsured mother with type 2 diabetes and a low income. It is not a way to get a weight-loss drug free, and an application built on weight alone has nothing to match.

Federal poverty guidelines by household size

Assistance programs judge income against the federal poverty guidelines, and household size changes the line a lot. A mother of three in a family of five can earn more than twice what a single adult can and still sit at the same percentage. Novo's page points applicants to these guidelines without printing its own cutoff, so ask the program which multiple applies before you assume you're over or under.

Figures are for the 48 contiguous states and Washington, DC; Alaska and Hawaii are higher.⁶ The 200% and 400% columns are our arithmetic, shown because those multiples come up often. They are not a statement of any one program's rule.

Medicare: the $50 bridge

Medicare members were long shut out of both cards. Since July 1, 2026, a CMS demonstration called the Medicare GLP-1 Bridge has filled part of that gap. It runs through December 2027, and eligible Part D members can get certain GLP-1s for weight management for $50 a month. On Lilly's side that means Zepbound KwikPen and Foundayo, for people who meet BMI and clinical criteria.⁷ Novo's Wegovy savings page also tells Medicare members they may be able to pay $50 a month.² If you have sleep apnea, type 2 diabetes or MASH, your Part D plan is the route instead.

When self-pay is the real answer

For a commercially insured mother whose plan excludes weight drugs, or an uninsured one above the income limits, self-pay through the manufacturers is the floor. It is far lower than list price.

The Zepbound $449 rate depends on refilling within 45 days.⁸ The Wegovy prices come from Novo's own terms.² TrumpRx lists the same brands at matching starting prices, from $149 for the Wegovy pill to $299 for Zepbound, and hands the order to the manufacturer's program.⁹

Price the dose you will actually stay on, not the starter dose. In a KFF poll published in November 2025, 56% of GLP-1 users said the drugs were difficult to afford. Fourteen percent of respondents using a GLP-1 said they had stopped because of the cost.¹⁰ Our full breakdown is in how much a GLP-1 costs without insurance. Compare programs that work with insurance on the GLP-1 with insurance board, or the lowest cash prices on the cheapest GLP-1 board.